Skip to content
Menu Close
  • About us
    • Our Journey
    • Board of Directors
    • Leadership
    • Governance
    • Manufacturing
    • R&D
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainability
  • Investors
    • Financials
    • Disclosures under Regulation 46 of SEBI LODR
    • Investor Resources
    • Other Announcements
  • News
    • Press Release
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • About us
    • Our Journey
    • Board of Directors
    • Leadership
    • Governance
    • Manufacturing
    • R&D
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainability
  • Investors
    • Financials
    • Disclosures under Regulation 46 of SEBI LODR
    • Investor Resources
    • Other Announcements
  • News
    • Press Release
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
Menu Close
  •  Global
    • India 
    • US 
    • Canada canada_flag
    • Europe   
    • Emerging Markets
      • Asia – Pacific
      • Latin America
      • Middle East & Africa
      • Russia & CIS
  •  Global
    • India 
    • US 
    • Canada canada_flag
    • Europe   
    • Emerging Markets
      • Asia – Pacific
      • Latin America
      • Middle East & Africa
      • Russia & CIS
  • Global

More results...

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
page
Connect with Us
  • About us
    • Our journey
    • Board of Directors
    • Leadership Team
    • Governance
    • Manufacturing
    • R&D Locations
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainibility
  • Investors
    •  Financials
      • Quarterly Results
      • Investor Presentations
      • Annual Report
    • Disclosure under Regulation 46 of SEBI (LODR) Regulations, 2015
    • Investor Resources
    •  Other announcements
      • 2026
      • 2025
      • 2024
      • 2023
  • News
    •  Press Release
      • 2026
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • Contact Us
  • IGI
  • Global
    • India   
    • U.S   
    • Canada   canada_flag
    • Europe   
    • Emerging Markets
      • Asia -Pacific
      • Latin America
      • Middle East & Africa
      • Russia & CIS
  • About us
    • Our journey
    • Board of Directors
    • Leadership Team
    • Governance
    • Manufacturing
    • R&D Locations
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainibility
  • Investors
    •  Financials
      • Quarterly Results
      • Investor Presentations
      • Annual Report
    • Disclosure under Regulation 46 of SEBI (LODR) Regulations, 2015
    • Investor Resources
    •  Other announcements
      • 2026
      • 2025
      • 2024
      • 2023
  • News
    •  Press Release
      • 2026
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • Contact Us
  • IGI
  • Global
    • India   
    • U.S   
    • Canada   canada_flag
    • Europe   
    • Emerging Markets
      • Asia -Pacific
      • Latin America
      • Middle East & Africa
      • Russia & CIS

Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials

  • Post author:glenmark2025
  • Post published:October 23, 2025
  • Post category:

Continue ReadingGlenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials

Glenmark Pharma is first to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes in Adults with Co-morbidities

  • Post author:glenmark2025
  • Post published:October 18, 2023
  • Post category:

Continue ReadingGlenmark Pharma is first to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes in Adults with Co-morbidities

Glenmark Pharma is first to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes in Adults with Co-morbidities

  • Post author:glenmark2025
  • Post published:October 18, 2023
  • Post category:

Continue ReadingGlenmark Pharma is first to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes in Adults with Co-morbidities

Glenmark Pharmaceuticals receives ANDA approval for Apremilast Tablets, 10 mg, 20 mg and 30 mg

  • Post author:glenmark2025
  • Post published:October 17, 2023
  • Post category:

Continue ReadingGlenmark Pharmaceuticals receives ANDA approval for Apremilast Tablets, 10 mg, 20 mg and 30 mg

Glenmark Pharmaceuticals receives ANDA approval for Apremilast Tablets, 10 mg, 20 mg and 30 mg

  • Post author:glenmark2025
  • Post published:October 17, 2023
  • Post category:

Continue ReadingGlenmark Pharmaceuticals receives ANDA approval for Apremilast Tablets, 10 mg, 20 mg and 30 mg

Ichnos Sciences Enters Licensing Agreement For OX40 Antagonist Monoclonal Antibody Portfolio with Astria Therapeutics OCT 23

  • Post author:glenmark2025
  • Post published:October 12, 2023
  • Post category:

Continue ReadingIchnos Sciences Enters Licensing Agreement For OX40 Antagonist Monoclonal Antibody Portfolio with Astria Therapeutics OCT 23

Newspaper Advertisement – Postal Ballot Notice

  • Post author:glenmark2025
  • Post published:October 9, 2023
  • Post category:

Continue ReadingNewspaper Advertisement – Postal Ballot Notice

Notice of Postal Ballot – Disclosure under Regulation 30 of the SEBI LODR Regulations, 2015

  • Post author:glenmark2025
  • Post published:October 6, 2023
  • Post category:

Continue ReadingNotice of Postal Ballot – Disclosure under Regulation 30 of the SEBI LODR Regulations, 2015

Credit Ratings -rating rationale issued by India Ratings and Research.

  • Post author:glenmark2025
  • Post published:October 3, 2023
  • Post category:

Continue ReadingCredit Ratings -rating rationale issued by India Ratings and Research.

Glenmark Pharmaceuticals launches Fingolimod Capsules, 0.5 mg in the US

  • Post author:glenmark2025
  • Post published:October 31, 2022
  • Post category:

Continue ReadingGlenmark Pharmaceuticals launches Fingolimod Capsules, 0.5 mg in the US
  • 1
  • 2
  • 3
  • Go to the next page

Glenmark Pharmaceuticals Ltd. is a research‐led, global pharmaceutical company, having a presence across Branded, Innovative, and Generics segments with a focus on therapeutic areas of respiratory, dermatology and oncology

Linkedin-in Instagram Youtube

About us

  • Our Journey
  • Board of Directors
  • Leadership
  • Governance
  • Manufacturing
  • R&D

Innovation

  • Overview
  • Pipeline
  • Partnerships

Products

  • Portfolio
  • Top Brands

Responsibility

  • Corporate Social Responsibility
  • Sustainability

Investors

  • Financials
  • Disclosures under Regulation 46
    of SEBI LODR
  • Investor Resources
  • Other announcements

News

  • Press Release
  • Media Library

Careers

  • Life at Glenmark
  • Glenmark Centre for Learning
Join Us

CAUTION NOTICE REGARDING FRAUDULENT RECRUITMENT

This is to notify to the public that certain unscrupulous persons, purporting to be part of and/or being authorised by the human resources department of Glenmark Pharmaceuticals Limited (“Glenmark”) are fraudulently offering jobs via certain websites/or through telephone calls, SMS or fake letters and asking the prospective job aspirants to appear for a face-to-face interview for a job opening with Glenmark and/or to pay a fee for securing a job with Glenmark. We wish to caution the public that Glenmark does not collect any monies or any other valuables as a pre or post-employment requirement.

Click Here to Know More        Click Here to Join Us

Download Factsheet
  • Privacy Portal
  • Terms & Conditions
  • Report a Concern
  • Report an Adverse Event
  • Investigator Initiated Trials
© 2026 Glenmark Pharmaceuticals Ltd. All Rights Reserved.
  • About Us
  • Innovation
  • Products
  • Responsibility
  • Investors
  • News
  • Careers
  • Terms & Conditions
  • Report a Concern
  • Report an Adverse Event
  • Investigator Initiated Trials
  • Privacy Portal
Download Factsheet
Linkedin-in Instagram Youtube
© 2026 Glenmark Pharmaceuticals Ltd.
All Rights Reserved.
  • About us
    • Our journey
    • Board of Directors
    • Leadership Team
    • Governance
    • Manufacturing
    • R&D Locations
  • Innovation
    • Overview
    • Pipeline
    • Partnerships
  • Products
    • Portfolio
    • Top Products
  • Responsibility
    • Corporate Social Responsibility
    • Sustainibility
  • Investors
    •  Financials
      • Quarterly Results
      • Investor Presentations
      • Annual Report
    • Disclosure under Regulation 46 of SEBI (LODR) Regulations, 2015
    • Investor Resources
    •  Other announcements
      • 2026
      • 2025
      • 2024
      • 2023
  • News
    •  Press Release
      • 2026
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
    • Media Library
  • Careers
    • Life at Glenmark
    • Glenmark Center for Learning
    • Join Us
  • Contact Us
  • IGI
  • Global
    • India   
    • U.S   
    • Canada   canada_flag
    • Europe   
    • Emerging Markets
      • Asia -Pacific
      • Latin America
      • Middle East & Africa
      • Russia & CIS
Type your search

CAUTION NOTICE REGARDING FRAUDULENT RECRUITMENT

This is to notify to the public that certain unscrupulous persons, purporting to be part of and/or being authorised by the human resources department of Glenmark Pharmaceuticals Limited (“Glenmark”) are fraudulently offering jobs via certain websites/or through telephone calls, SMS or fake letters and asking the prospective job aspirants to appear for a face-to-face interview for a job opening with Glenmark and/or to pay a fee for securing a job with Glenmark. We wish to caution the public that Glenmark does not collect any monies or any other valuables as a pre or post-employment requirement.

Click Here to Know More        Click Here to Join Us